9-aminocamptothecin has been researched along with Anemia in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hochster, H; Mandeli, J; Muggia, FM; Plimack, ER; Runowicz, CD; Sorich, J; Speyer, J; Wadler, S; Wallach, RC; Wright, J | 1 |
Bartel, S; Bharti, A; Hurwitz, S; Levy, S; Lynch, C; Rosowsky, A; Rubin, E; Toppmeyer, D; Trites, D; Wood, V | 1 |
2 trial(s) available for 9-aminocamptothecin and Anemia
Article | Year |
---|---|
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Camptothecin; Carcinoma; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Treatment Outcome | 2004 |
A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 1995 |